Mechanism of Action
Lipopolysaccharide-Triggered Pore Formation
PG-1 binds LPS on Gram-negative bacteria and inserts into the outer membrane. The beta-hairpin structure, stabilized by two disulfide bonds, forms amyloid-like dimers that aggregate into toroidal pores in the inner membrane. The arginine-rich termini provide electrostatic targeting to anionic bacterial membranes. Sub-lethal concentrations cause membrane depolarization and permeabilization, while higher concentrations cause rapid lysis.
Structural Stability Advantage
The beta-hairpin conformation stabilized by disulfide bonds confers protease resistance compared to linear AMPs, extending biological activity. This stability was a key rationale for clinical development. The compact structure also limits immune system recognition.
Research Summary
Broad-Spectrum Potency
PreclinicalPG-1 exhibits MIC values of 0.1-1 ug/mL against E. coli, P. aeruginosa, S. aureus, and C. albicans. Activity against antibiotic-resistant strains including MRSA and VRE is maintained, making it a candidate for last-resort therapeutic development. Structural analogs with altered amino acid composition have been explored to reduce mammalian cell toxicity.
Iseganan Phase III for Oral Mucositis
Phase III (Failed)Iseganan (IB-367), a protegrin analog, was developed by IntraBiotics Pharmaceuticals for prevention of oral mucositis in cancer patients undergoing radiation and chemotherapy. The Phase III PRISM trial (>600 patients) showed no significant reduction in the primary endpoint of severe oral mucositis. The failure was attributed to complex microbiome interactions and pH variability in the oral cavity affecting drug activity, not fundamental peptide toxicity.
Calculate your Protegrin dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Antimicrobial testing (in vitro) | 0.1-2 ug/mL MIC | Single exposure | Direct application |
| Oral mucositis (clinical trial) | 0.3 mg/mL oral rinse | Multiple daily | Oral rinse |
Clinical dosing from Iseganan Phase III trial. No approved human use.
Interactions
Safety Profile
Topical application was well tolerated in Phase III trials. Systemic hemolytic toxicity limits parenteral use. The beta-hairpin scaffold is being explored to design analogs with improved therapeutic index. No regulatory approval for any indication.
References
- [1]Lehrer RI, et al. (1993). Protegrins: cysteine-containing antimicrobial peptides from porcine leukocytes. Infect Immun, 61(4), 1433-1442.
- [2]Trotti A, et al. (2004). Iseganan HCl oral solution for the reduction of severe oral mucositis in patients undergoing radiation therapy for head and neck malignancies. Int J Radiat Oncol Biol Phys, 58(5), 1407-1413.